Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Lexagene Holdings Inc V.LXG


Primary Symbol: LXXGQ

Lexagene Holdings Inc. is a molecular diagnostics company engaged in researching, developing and commercializing automated genetic analyzer devices in clinical and life science industries. The Company is focused on developing molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, and for use in open-access markets such as food and water safety, clinical research, agricultural testing and biodefense. The Company's MiQLab System is an automated, open-access molecular diagnostic system for pathogen detection, allowing users to test for multiple pathogens onsite, returning results in approximately 2 hours. Its MiQLab System is an automated, multiplexing polymerase chain reaction (PCR)-based system designed for syndromic testing in human clinical diagnostics and veterinary diagnostics, as well as food safety testing, and open-access custom testing markets.


GREY:LXXGQ - Post by User

Comment by laurencelefouon Feb 28, 2023 7:12am
338 Views
Post# 35308899

RE:RE:RE:RE:New Press Release - LexaGene Files for Chapter 7 Bankruptcy

RE:RE:RE:RE:New Press Release - LexaGene Files for Chapter 7 Bankruptcy
Just saw on rally-co.ca that LexaGene has filled for bankruptcy.  I do not know this company, but as a rule, I never invest in a company that is not profitable or has enough cash to cover expenses for at least one year.
 
Looking at the November 30, 2022, Financial Statements, LexaGene had cash of US$464,131, accounts receivable of US$51,643, accounts payable of US$272,170, lease liabilities of US$350,000, and the business activity lost US$1,672,677.   For the last nine months, net cash used in operating activities showed a loss of US$5,063,871.   Since February 2022, the company’s cash balance has gone from US$4,722,710 to US$464,131.


There are plenty of companies with good Balance Sheets so why risk your money with speculative companies?
 
https://www.rally-co.ca/post/lxg-v-bankruptcy

<< Previous
Bullboard Posts